Clinical Trial

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase I trial tests the safety, side effects, and best dose of MTI-301 in treating patients with solid cancers that have spread from where they first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and that have not responded to previous treatment (refractory). MTI-301 is a drug that inhibits an enzyme called SCD1. SCD1 is an enzyme that promotes tumor growth and spread and is upregulated in some cancer types. MTI-301 may disrupt the activity of SCD1, which may lead to reduced tumor growth and/or spread.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-28; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-07
Trial Details
NCT Number NCT06911008
Lead Sponsor Mayo Clinic
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Enrollment 42 participants
Start Date 2025-11-07
Primary Completion 2027-04-09 (estimated)
Study Completion 2027-04-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-19